Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Laura M McNamee"'
Autor:
Ekaterina Galkina Cleary, Laura M McNamee, Skyler de Boer, Jeremy Holden, Liam Fitzgerald, Fred D Ledley
Publikováno v:
PLoS ONE, Vol 16, Iss 1, p e0243813 (2021)
We compared the financial performance of 319 BIOTECH companies focused on developing therapeutics with IPOs from 1997-2016, to that of paired, non-biotech CONTROL companies with concurrent IPO dates. BIOTECH companies had a distinctly different finan
Externí odkaz:
https://doaj.org/article/f9e530faa4df411babc656bd54b0c721
Autor:
Laura M McNamee, Fred D Ledley
Publikováno v:
PLoS ONE, Vol 12, Iss 3, p e0174538 (2017)
This work examines translational science in cancer based on theories of innovation that posit a relationship between the maturation of technologies and their capacity to generate successful products. We examined the growth of technologies associated
Externí odkaz:
https://doaj.org/article/27a653472ced48b99d6e28dca36fa482
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0177371 (2017)
While timelines for clinical development have been extensively studied, there is little data on the broader path from initiation of research on novel drug targets, to approval of drugs based on this research. We examined timelines of translational sc
Externí odkaz:
https://doaj.org/article/4e7a0e8d5f2b4c4bab7f44d388ee25c6
Autor:
Skyler de Boer, Ekaterina Galkina Cleary, Liam Fitzgerald, Laura M. McNamee, Jeremy Holden, Fred D. Ledley
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 1, p e0243813 (2021)
PLoS ONE, Vol 16, Iss 1, p e0243813 (2021)
We compared the financial performance of 319 BIOTECH companies focused on developing therapeutics with IPOs from 1997–2016, to that of paired, non-biotech CONTROL companies with concurrent IPO dates. BIOTECH companies had a distinctly different fin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::438d24e7146f8837f03ebb0bd98131d1
http://europepmc.org/articles/PMC7787373
http://europepmc.org/articles/PMC7787373
Publikováno v:
Clinical therapeutics. 43(1)
Purpose This work describes the late-stage product portfolios of the biotechnology companies that completed initial public offerings (IPOs) from 1997 to 2016. We asked whether these emerging companies continue to develop innovative, biologic products
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f00b771dc78cc1a7ce8f1004d0d2c49a
https://pubmed.ncbi.nlm.nih.gov/33380363
https://pubmed.ncbi.nlm.nih.gov/33380363
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 9, Iss C, Pp 379-386 (2017)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41542af475a60288b0bcf8e5c0106223
http://www.sciencedirect.com/science/article/pii/S2162253117302810
http://www.sciencedirect.com/science/article/pii/S2162253117302810
Autor:
Ekaterina Galkina Cleary, Jennifer M. Beierlein, Fred D. Ledley, Laura M. McNamee, Navleen Surjit Khanuja
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance This report shows that NIH funding contributed to published research associated with every one of the 210 new drugs approved by the Food and Drug Administration from 2010–2016. Collectively, this research involved >200,000 years of gra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59bb9ef51fb11abf16a201d8a0ad13d7
https://pubmed.ncbi.nlm.nih.gov/32502441
https://pubmed.ncbi.nlm.nih.gov/32502441
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 5, p e0177371 (2017)
PLoS ONE, Vol 12, Iss 5, p e0177371 (2017)
While timelines for clinical development have been extensively studied, there is little data on the broader path from initiation of research on novel drug targets, to approval of drugs based on this research. We examined timelines of translational sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe90cb6789a386eb4104e90ab8e7b64
http://europepmc.org/articles/PMC5421779
http://europepmc.org/articles/PMC5421779
Autor:
Joseph A. DiMasi, Fred D. Ledley, Jennifer M. Beierlein, Michael J. Walsh, Kenneth I. Kaitin, Laura M. McNamee
Publikováno v:
Clinical therapeutics. 39(7)
Purpose This study examines the complete timelines of translational science for new cardiovascular therapeutics from the initiation of basic research leading to identification of new drug targets through clinical development and US Food and Drug Admi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3b2fec508d56cfdf1aa96c8f7456b20
https://pubmed.ncbi.nlm.nih.gov/28652015
https://pubmed.ncbi.nlm.nih.gov/28652015
Publikováno v:
Gene Therapy. 21:188-194
This report examines the commercialization of gene therapy in the context of innovation theories that posit a relationship between the maturation of a technology through its life cycle and prospects for successful product development. We show that th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b398f11a6c4371f47f55bae47f5bb4f
https://doi.org/10.1038/gt.2013.72
https://doi.org/10.1038/gt.2013.72